Virus-Like Particles as an Instrument of Vaccine Production

Abstract

The paper discusses the techniques which are currently implemented for vaccine production based on virus-like particles (VLPs). The factors which determine the characteristics of VLP monomers assembly are provided in detail. Analysis of the literature demonstrates that the development of the techniques of VLP production and immobilization of target antigens on their surface have led to the development of universal platforms which make it possible for virtually any known antigen to be exposed on the particle surface in a highly concentrated form. As a result, the focus of attention has shifted from the approaches to VLP production to the development of a precise interface between the organism's immune system and the peptides inducing a strong immune response to pathogens or the organism's own pathological cells. Immunome-specified methods for vaccine design and the prospects of immunoprophylaxis are discussed. Certain examples of vaccines against viral diseases and cancers are considered.

Global efforts on vaccines for COVID-19: Since, sooner or later, we all will catch the coronavirus

“…One of the problems of using the protein subunit vaccine has been presenting the antigen in its most stable and effective conformation. VLPs are composed of multiple structural proteins, which upon recombinant expression have the ability to selfassemble into nanostructures enclosing the capsid proteins within itself (Syomin and Ilyin 2019). The VLPs can have a lipid envelope originating from the cell membrane producing them in the form of budding and can also be chimeric in nature, displaying an envelope protein from another virus.…”

The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies

“…Also, it can fold the antigenic proteins of several microorganisms, such as bacteria, fungi, insects, mammalian cell lines, and even in transgenic plants. VLPs can act as non-replicating vectors for subunit and live-attenuated vaccine production in the absence of its genome [171] .…”

Topical review on nano-vaccinology: Biochemical promises and key challenges

“…Admirable performance explored in pre-clinical and clinical trials, liposomal and VLPs based nano-vaccines, there are more than 10 commercial vaccines in human practice or clinical trials. Classical examples to VLP-based commercial vaccines include the porcine-circo virus vaccine, human cervical cancer and anti-hepatitis B nano-vaccines and multi-epitope anti-malarial and anti-hepatitis B vaccines [ 19 , 20 ]. The desired level of epitope density and co-stimulation is a very unique and high precision characteristic of nano-based vaccines.…”